Arbutus Biopharma
ABUS
ABUS
167 hedge funds and large institutions have $390M invested in Arbutus Biopharma in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 52 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
167
Holders Change
+14
Holders Change %
+9.15%
% of All Funds
2.27%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
26
Increased
46
Reduced
52
Closed
9
Calls
$3.1M
Puts
$2.26M
Net Calls
+$835K
Net Calls Change
+$778K
Top Buyers
| 1 |
FC
Foursixthree Capital
New York
|
+$8.55M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$5.88M |
| 3 |
Goldman Sachs
New York
|
+$5.39M |
| 4 |
Morgan Stanley
New York
|
+$4.21M |
| 5 |
TSC
Two Seas Capital
Rye,
New York
|
+$2.53M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$2.31M |
| 2 |
JPMorgan Chase & Co
New York
|
-$1.25M |
| 3 |
BlackRock
New York
|
-$596K |
| 4 |
Squarepoint
New York
|
-$561K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$517K |
